Identifying Different Immunoresistance Risk Profiles Among Experienced Aesthetic Botulinum Neurotoxin A Recipients: A Latent Class Analysis.
Abstract
[BACKGROUND] Immunoresistance to botulinum neurotoxin A (BoNT-A) due to neutralizing antibodies (NAbs) can lead to partial or complete secondary nonresponse (SNR), potentially limiting individuals' aesthetic and/or medical therapeutic options in the short and/or long term. Understanding factors directly or indirectly influencing BoNT-A immunoresistance risk is crucial.
[AIMS] This analysis explored patterns of latent risk factors (biological and behavioral) that may influence the risk of developing BoNT-A immunoresistance among experienced aesthetic BoNT-A recipients.
[METHODS] Latent class analysis (LCA) was applied to survey data from 363 experienced BoNT-A recipients from six Asia-Pacific countries to identify distinct subgroups based on their patterns of risk factor or risk proxy variables. The five risk proxy variables used for modeling capture information on BoNT-A treatments (treatment indications/locations as proxies for dose), symptoms of declining efficacy, number of aesthetic treatments over the past 3 years, and clinic and BoNT-A formulation switching behaviors. These represent established risk factors and treatment-seeking behaviors suggested to influence immunoresistance risk.
[RESULTS] LCA identified 3 distinct profiles of individuals, which we described based on the observed patterns of risk proxies as: "lower-risk" (55%), "moderate-risk" (39%), and "higher-risk" (6%). Individuals in the "higher-risk" profile reported higher BoNT-A exposure, more symptoms of declining efficacy, and distinct patterns of knowledge and attitudes toward BoNT-A immunoresistance that could account for their treatment-seeking behaviors.
[CONCLUSIONS] This study suggests that individual behaviors (the "human factor") have a notable influence on BoNT-A immunoresistance risk. Gaining deeper insights into these factors could support more targeted and effective interventions to mitigate risk.
[AIMS] This analysis explored patterns of latent risk factors (biological and behavioral) that may influence the risk of developing BoNT-A immunoresistance among experienced aesthetic BoNT-A recipients.
[METHODS] Latent class analysis (LCA) was applied to survey data from 363 experienced BoNT-A recipients from six Asia-Pacific countries to identify distinct subgroups based on their patterns of risk factor or risk proxy variables. The five risk proxy variables used for modeling capture information on BoNT-A treatments (treatment indications/locations as proxies for dose), symptoms of declining efficacy, number of aesthetic treatments over the past 3 years, and clinic and BoNT-A formulation switching behaviors. These represent established risk factors and treatment-seeking behaviors suggested to influence immunoresistance risk.
[RESULTS] LCA identified 3 distinct profiles of individuals, which we described based on the observed patterns of risk proxies as: "lower-risk" (55%), "moderate-risk" (39%), and "higher-risk" (6%). Individuals in the "higher-risk" profile reported higher BoNT-A exposure, more symptoms of declining efficacy, and distinct patterns of knowledge and attitudes toward BoNT-A immunoresistance that could account for their treatment-seeking behaviors.
[CONCLUSIONS] This study suggests that individual behaviors (the "human factor") have a notable influence on BoNT-A immunoresistance risk. Gaining deeper insights into these factors could support more targeted and effective interventions to mitigate risk.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 약물 | LCA
→ Latent class analysis
|
C4704739
Latent Class Analysis
|
scispacy | 1 | |
| 약물 | [BACKGROUND] Immunoresistance
|
scispacy | 1 | ||
| 약물 | BoNT-A
→ botulinum neurotoxin A
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 질환 | treatment-seeking behaviors
|
scispacy | 1 | ||
| 질환 | individual behaviors
|
scispacy | 1 | ||
| 기타 | Botulinum Neurotoxin A Recipients: A Latent Class
|
scispacy | 1 | ||
| 기타 | botulinum neurotoxin A
|
scispacy | 1 | ||
| 기타 | BoNT-A
→ botulinum neurotoxin A
|
scispacy | 1 | ||
| 기타 | BoNT-A recipients
|
scispacy | 1 | ||
| 기타 | human
|
scispacy | 1 |
MeSH Terms
Humans; Botulinum Toxins, Type A; Female; Latent Class Analysis; Male; Adult; Middle Aged; Risk Factors; Antibodies, Neutralizing; Cosmetic Techniques; Young Adult; Surveys and Questionnaires